article thumbnail

BioOrbit eyes 2026 for pre-clinical trials of space manufactured protein crystals

Pharmaceutical Technology

BioOrbit aims to kick off pre-clinical trials to study protein crystals for monoclonal antibodies (mAbs) produced in a pharmaceutical factory in space in 2026. Then, we will need to run pre-clinical trials of these crystals, which will be in 2026 or 2027. Image credit: Rini. com/ Shutterstock.

article thumbnail

USP announces new Advanced Technologies Laboratory to accelerate and scale pharmaceutical manufacturing innovations

Pharmacy Times

The Advanced Technologies Lab will help industry and regulators accelerate the adoption of new technologies that help to mitigate supply chain risks and, where appropriate, establish guidance that supports regulatory predictability, process efficiencies, and faster time to market, all of which can strengthen domestic manufacturing capabilities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What Pharma Manufacturers Need to Know About US Trade Policy Changes

PharmaTech

In this first segment of a multi-part interview, Jason Waite, international trade expert at Alston & Bird, outlines how recent United States tariff activity could significantly impact pharmaceutical manufacturers.

article thumbnail

Actio gains $66m to advance small molecule therapeutics pipeline

Pharmaceutical Technology

By GlobalData Learn more about Strategic Intelligence The company then plans to expand into a Phase Ib proof-of-concept trial in patients with KCNT1-related epilepsy in early 2026. The US Food and Drug Administration (FDA) has awarded ABS-1230 both orphan drug and rare paediatric designations.

article thumbnail

Draig secures $140m for neuropsychiatric disorder therapies

Pharmaceutical Technology

As well as advancing DT-101, the new capital injection will also support the progression of two gamma-aminobutyric acid type A (GABA A ) receptor modulators towards clinical trials in 2026. These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options.

article thumbnail

SAVE THE DATE: Drug Channels Leadership Forum, March 16-18, 2026

Drug Channels

After a blockbuster inaugural event and tremendous feedback from attendees, were excited to announce that the Drug Channels Leadership Forum (DCLF) returns on March 1618, 2026 , at the Turnberry Resort & Spa in Miami. Join us at DCLF 2026 Invitations will begin going out in October 2025. GET STARTED Be part of the conversation!

article thumbnail

WuXi STA breaks ground on new Delaware manufacturing facility

European Pharmaceutical Review

Contract research, development and manufacturing organisation (CRDMO) WuXi STA has broken ground on its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, US. WuXi STA has 12 sites across the US, Europe and Asia. This campus is only possible because of Delaware’s world-class, innovative workforce.